Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.8552W HIGH $21.27
Volume
1.76 M
Value Traded
53.68 M
Short % Float
25.93%
-5.7%Week
-4.18%1 Month
-10.62%3 Month
+19.68%6 Month
-56.75%5 Year
-61.34%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.92 B
EPS (TTM)
-1.31
P/E Ratio
-
Ent. Value
3.01 B
Total Shares
219.26 M
Float Shares
171.59 M
Insiders
21.70%
Institutions
99.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RLAY Catalyst Timeline
Dated clinical, regulatory and corporate events for Relay Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Relay Therapeutics, Inc.
325Total events
8Upcoming
63Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationZovegalisibTrial
Relay Therapeutics initiates Phase 3 clinical trial of zovegalisib (RLY-2608)
breast cancersource ↗
▲Milestone PaymentZovegalisibCorporate
Milestone achieved under X-Chem/Relay Research Collaboration and License Agreement following Phase 3 initiation
breast cancersource ↗
▲Trial InitiationZovegalisibTrial
Relay Therapeutics initiates Phase 3 clinical trial of zovegalisib (RLY-2608)
PI3Ka-driven diseases / breast cancersource ↗
▲Enrollment MilestoneZovegalisibTrial
Opened expansion cohorts for adults and adolescents in ReInspire trial
vascular anomaliessource ↗
▲Partnership / LicenseCorporate
Pfizer agreed to supply atirmociclib for planned Phase 3 1L trial
1L breast cancersource ↗
▲Topline ReadoutZovegalisibClinical Data
Presented triplet combination data with 44% ORR in heavily pre-treated patients
3L breast cancer (PI3Kα-mutated, HR+/HER2-)source ↗
◆Oral PresentationPresentation
Relay Therapeutics management to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Relay Therapeutics management to participate in Jefferies Global Healthcare Conference fireside chat
◆Poster PresentationZovegalisibPresentation
Preclinical data on Zovegalisib in murine models of PIK3CA-mutant vascular malformations
PIK3CA-mutant vascular malformationssource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 22,916,667 shares at $12.00 per share
◆Oral PresentationZovegalisibPresentation
Initial Results of Zovegalisib in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations
PIK3CA-driven vascular malformationssource ↗
▼Equity OfferingCorporate
Relay Therapeutics announces proposed public offering of $175 million common stock
◆Oral PresentationZovegalisibPresentation
Initial clinical data presented at ISSVA World Congress 2026
PIK3CA-driven vascular anomaliessource ↗
●Enrollment UpdateZovegalisibTrial
Pediatric dose-finding (Part 1) for ages 6-11 ongoing
PIK3CA-driven vascular anomaliessource ↗
▲Breakthrough Therapy DesignationZovegalisibDesignation
FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer
PIK3CA-mutant, HR+/HER2- advanced breast cancersource ↗
▲Trial InitiationRLY-8161Trial
Initiated Phase 1/2 trial of RLY-8161 in patients with NRAS-mutant solid tumors
NRAS-mutant solid tumorssource ↗
▼Equity OfferingCorporate
Raised approximately $316 million in underwritten follow-on public offering in May 2026
▲Partnership / LicenseCorporate
Supply agreement with Pfizer for atirmociclib and palbociclib for Phase 3 trial
▲Topline ReadoutZovegalisibClinical Data
Initial efficacy data: 60% volumetric response rate at 12 weeks
PIK3CA-driven vascular anomaliessource ↗
▲Topline ReadoutZovegalisibClinical Data
Clinical data for zovegalisib + atirmociclib + fulvestrant triplet from ReDiscover dose-finding
PI3Kα-mutated, HR+/HER2- metastatic breast cancersource ↗
◆Oral PresentationZovegalisibPresentation
Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed dose to be presented at ESMO Targeted Anticancer Therapies Congress
PIK3CA-mutant, HR+/HER2- advanced breast cancersource ↗
◆Oral PresentationPresentation
Relay Therapeutics management to participate in two investor conferences in March 2026
▲Oral PresentationZovegalisibPresentation
Presented zovegalisib doublet data at ESMO TAT Congress 2026
PIK3CA-mutant, HR+/HER2- metastatic breast cancersource ↗
▲Breakthrough Therapy DesignationZovegalisibDesignation
Breakthrough Therapy designation from FDA for zovegalisib
◆Oral PresentationPresentation
Relay Therapeutics management to participate in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
▲Breakthrough Therapy DesignationZovegalisibDesignation
FDA granted Breakthrough Therapy designation for zovegalisib in combination with fulvestrant
PIK3CA-mutant, HR+/HER2- advanced breast cancersource ↗
▲Topline ReadoutZovegalisibClinical Data
Data cut-off January 13, 2026: median PFS 11.1 months, ORR 43%
PI3Kα-mutated, HR+/HER2- metastatic breast cancersource ↗
◆Topline ReadoutZovegalisibClinical Data
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies
PIK3CA-driven vascular anomaliessource ↗
▼Equity OfferingCorporate
Net proceeds of $137.1 million from at-the-market offerings in Q1 2026
▲Oral PresentationZovegalisibPresentation
Presented initial positive clinical data from Phase 1/2 ReInspire trial at ISSVA World Congress 2026
vascular anomaliessource ↗
▲Enrollment MilestoneZovegalisibTrial
Opened expansion cohorts for adults and adolescents in ReInspire trial
vascular anomaliessource ↗
▲Oral PresentationZovegalisibPresentation
Subset analysis of zovegalisib + fulvestrant presented at SABCS 2025
PI3Kα-mutated, HR+/HER2- metastatic breast cancersource ↗
●Enrollment UpdateZovegalisibTrial
Continued enrollment in Phase 3 ReDiscover-2 trial
PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancersource ↗
●Dose Finding UpdateZovegalisibTrial
Continued dose escalation and advancing triplet cohorts in ReDiscover trial
PI3Kα-mutated, HR+/HER2- advanced breast cancersource ↗
◆Oral PresentationPresentation
Management to participate in two upcoming investor conferences in November
●Enrollment UpdateZovegalisibTrial
118 patients enrolled in zovegalisib + fulvestrant arm as of October 15, 2025
PI3Kα-mutated, HR+/HER2- metastatic breast cancersource ↗
●Trial InitiationZovegalisibTrial
Phase 3 ReDiscover-2 trial ongoing
HR+/HER2- metastatic breast cancersource ↗
◆Trial InitiationTrial
Clinical start for non-inhibitory chaperone for Fabry disease
Fabry diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How RLAY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-22 | Zovegalisib (RLY-2608) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$278M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 55%
Small Cap(rank 362 of 658)
Percentile Rank
Relay Therapeutics, Inc. faces pipeline headwinds (35/100), with $428M risk-adjusted pipeline value, led by RLY-8161 in Advanced NRAS-Mutant Melanoma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RLY-8161 Small moleculeNCT07584226 | Advanced NRAS-Mutant Melanoma | Phase 1 | RECRUITING | 35 | Dec 31, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every RLAY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zovegalisib Breakthrough | PIK3CA-driven vascular anomalies | Phase 2 | 2026-05-19 | volumetric response rate: 60%; clinical improvement: 89%; safety profile: no patients discontinuing treatment due to adverse eventsRead More | Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular AnomaliesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Patel SanjivDirector, Officer (President and CEO) | Sell | -48,199 471,301 held | $18.10 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RLAY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 15 % (37.6 %) | 300.02 M | 16.04 M | 11.21% ( 1.62 M) |
RLAY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RLAY ranks across every disease it competes in
Competitive Position is a premium feature
See how RLAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRLAY News
RLAY▲ +5.9%on this news
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
X-Chem has announced a significant milestone with Relay Therapeutics, marking the initiation of a Phase 3 clinical trial for zovegalisib, an inhibitor targeting PI3Ka. This drug candidate was developed from a compound identified through X-Chem's DNA-encoded chemical library. The collaboration underscores the innovative approaches both companies are taking in drug discovery.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics announced participation in two upcoming investor conferences in September 2026. The events include the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. These fireside chats will be webcast live, showcasing the company's advancements in precision medicine and ongoing clinical trials.
Read more →RLAYRelay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics announced its Q2 2026 financial results, highlighting advancements in its zovegalisib program for breast cancer and vascular anomalies. The company plans to initiate a Phase 3 trial for first-line breast cancer in early 2027, contingent on regulatory feedback. Despite a net loss of $83.7 million, Relay maintains a strong cash position, ensuring operational continuity through 2029.
Read more →RLAYRelay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Relay Therapeutics, a clinical-stage precision medicine company, will announce its second quarter 2026 financial results on August 6, 2026. The company focuses on developing therapies for cancer and genetic diseases. Its lead asset, zovegalisib, is in a Phase 3 trial for HR+/HER2- metastatic breast cancer and also targets genetic disease indications.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Relay Therapeutics will participate in two investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. The events will feature live webcasts available on the company's website. Relay Therapeutics is known for its innovative therapies targeting cancer and genetic diseases, with its lead asset, zovegalisib, in Phase 3 trials.
Read more →RLAYRelay Therapeutics Announces Pricing of Public Offering of Common Stock - May 20, 2026
Relay Therapeutics has announced the pricing of a public offering of 22,916,667 shares at $12.00 each, aiming to raise approximately $275 million. The offering is set to close around May 22, 2026, and includes a 30-day option for underwriters to purchase additional shares. Relay's lead asset, zovegalisib, is currently in Phase 3 trials for metastatic breast cancer.
Read more →RLAYRelay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics has announced the pricing of a public offering of 22,916,667 shares at $12.00 each, aiming to raise around $275 million. The offering includes a 30-day option for underwriters to purchase additional shares. The transaction is expected to close on May 22, 2026, pending customary conditions.
Read more →RLAY▲ +7.9%on this newsshared move
Relay Therapeutics Announces Proposed Public Offering of Common Stock - May 19, 2026
Relay Therapeutics has announced a public offering of $175 million in common stock, with an option for underwriters to purchase an additional 15%. The offering is being managed by notable financial institutions and is subject to market conditions. Relay's lead asset, zovegalisib, is currently in a Phase 3 trial for metastatic breast cancer.
Read more →RLAYRelay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Relay Therapeutics has reported promising initial clinical data for zovegalisib in treating PIK3CA-driven vascular anomalies. In the Phase 2 ReInspire trial, 60% of patients achieved a volumetric response, with 89% reporting clinical improvement at 12 weeks. The safety profile indicates potential for chronic use, with no patients discontinuing treatment due to adverse events.
Read more →RLAYRelay Therapeutics Announces Proposed Public Offering of Common Stock
Relay Therapeutics has announced a proposed public offering of $175 million in common stock. The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. The company aims to use the proceeds to support its clinical-stage development of therapies for cancer and genetic diseases, including its lead asset, zovegalisib, currently in Phase 3 trials.
Read more →RLAYRelay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer
Relay Therapeutics reported its financial results for Q1 2026, highlighting significant progress in developing zovegalisib, which received FDA Breakthrough Therapy designation for specific advanced breast cancer. The company also presented phase 3 data showcasing promising efficacy of zovegalisib in combination therapies. In addition, Relay Therapeutics initiated a Phase 1/2 trial for another compound, RLY-8161, addressing NRAS-mutant solid tumors. The financial results showed robust cash reserves, positioning the company well for future trials and developments.
Read more →RLAYRelay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Relay Therapeutics will announce its first quarter 2026 financial results and corporate highlights on May 5, 2026. The company focuses on developing precision medicine therapies for cancer and genetic diseases. Its lead asset, zovegalisib, is currently in a Phase 3 trial for metastatic breast cancer and is also being explored for genetic disease indications.
Read more →RLAYRelay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Relay Therapeutics announced promising clinical data for its triplet regimen of zovegalisib, atirmociclib, and an aromatase inhibitor in frontline metastatic breast cancer. The combination demonstrated a 44% overall response rate in heavily pre-treated patients, with plans to initiate a Phase 3 trial in early 2027. The data suggests a well-tolerated treatment option, although further regulatory feedback is required.
Read more →RLAYRelay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Relay Therapeutics announced that initial clinical results for zovegalisib will be presented at the ISSVA World Congress 2026. The data will include results from approximately 20 efficacy-evaluable patients. Zovegalisib is a mutant-selective PI3Kα inhibitor aimed at treating vascular anomalies and has shown potential in preclinical studies.
Read more →RLAYRelay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics presented data on zovegalisib (RLY-2608) combined with fulvestrant at the ESMO Targeted Anticancer Therapies Congress 2026. The Phase 3 ReDiscover-2 trial, which uses a 400mg BID fed dosage, demonstrated a median progression-free survival of 11.1 months among heavily pre-treated patients with metastatic breast cancer. The safety profile is consistent with prior trials, showing that the treatment is generally well-tolerated with manageable adverse effects. The results support the advancement of this promising regimen in the ongoing clinical trial.
Read more →RLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Relay Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting a significant cash position of approximately $555 million. The company outlined several key milestones for 2026, including the anticipated Phase 1 data for zovegalisib, which has received Breakthrough Therapy designation from the FDA. Initial data will also be presented for zovegalisib in PIK3CA-driven vascular anomalies and in combination with fulvestrant for metastatic breast cancer. Despite a report of substantial net losses and decreased cash reserves year-over-year, the company maintains a focus on long-term growth and commercialization of its therapies.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in March 2026
Relay Therapeutics announced its participation in two investor conferences scheduled for March 2026. The events will include live webcasts accessible via the company's website. Relay is known for its innovative therapies targeting cancer and genetic diseases, with its lead asset, zovegalisib, currently in a Phase 3 trial for metastatic breast cancer.
Read more →RLAYRelay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Relay Therapeutics, a clinical-stage company focused on precision medicine, will announce its fourth quarter and full year financial results for 2025 on February 26, 2026. This announcement will follow the close of U.S. financial markets, providing insights into the company's performance and corporate highlights for the fiscal year. As a company developing treatments for cancer and genetic diseases, this update is significant for stakeholders and investors alike.
Read more →RLAYRelay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The event will feature a live webcast of a fireside chat with the company's management. Relay is known for its innovative therapies targeting cancer and genetic diseases, including its lead asset, zovegalisib, currently in Phase 3 trials.
Read more →About Relay Therapeutics, Inc.
Headquarters60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
BIOPHARMAWATCH ELITE PLUS
Trade the next RLAY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime